Abstract
Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Current Drug Targets
Title: Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Volume: 7 Issue: 6
Author(s): Mathieu Vinken, Papeleu Peggy, Rogiers Vera and Vanhaecke Tamara
Affiliation:
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Abstract: Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Export Options
About this article
Cite this article as:
Vinken Mathieu, Peggy Papeleu, Vera Rogiers and Tamara Vanhaecke, Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435281
DOI https://dx.doi.org/10.2174/138945006777435281 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Current Topics in Medicinal Chemistry Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology
Reviews on Recent Clinical Trials Bladder Cancer: Molecular Determinants of Personalized Therapy
Current Drug Targets Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Human 5-HT4 and 5-HT7 Receptor Splice Variants: Are they Important?
Current Neuropharmacology Evidence that Bergapten, Independently of its Photoactivation, Enhances p53 Gene Expression and Induces Apoptosis in Human Breast Cancer Cells
Current Cancer Drug Targets 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Review of the Biological Activity of Maslinic Acid
Current Drug Targets NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry